Literature DB >> 10214708

An 225Ac/213Bi generator system for therapeutic clinical applications: construction and operation.

M R McDevitt1, R D Finn, G Sgouros, D Ma, D A Scheinberg.   

Abstract

A method for construction and operation of an 225Ac/213Bi generator capable of producing 25-100 mCi of 213Bi suitable for clinical antibody labeling is described. The generator has been designed to have an effective lifetime of several weeks, producing up to six therapeutic doses of radionuclide per day. To date, 57 clinical doses have been prepared and injected into patients using the described 213Bi generator. Factors such as radiation damage, radioprotection, iodide eluate chemistry, radiolabeling chemistry and radionuclide purity are addressed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10214708     DOI: 10.1016/s0969-8043(98)00151-1

Source DB:  PubMed          Journal:  Appl Radiat Isot        ISSN: 0969-8043            Impact factor:   1.513


  26 in total

Review 1.  An overview of targeted alpha therapy.

Authors:  Young-Seung Kim; Martin W Brechbiel
Journal:  Tumour Biol       Date:  2011-12-06

2.  Immunoliposomal delivery of 213Bi for alpha-emitter targeting of metastatic breast cancer.

Authors:  Mohanambe Lingappa; Hong Song; Sarah Thompson; Frank Bruchertseifer; Alfred Morgenstern; George Sgouros
Journal:  Cancer Res       Date:  2010-07-22       Impact factor: 12.701

Review 3.  Targeted alpha-therapy: past, present, future?

Authors:  Martin W Brechbiel
Journal:  Dalton Trans       Date:  2007-09-11       Impact factor: 4.390

4.  Targeting aberrant DNA double-strand break repair in triple-negative breast cancer with alpha-particle emitter radiolabeled anti-EGFR antibody.

Authors:  Hong Song; Mohammad Hedayati; Robert F Hobbs; Chunbo Shao; Frank Bruchertseifer; Alfred Morgenstern; Theodore L Deweese; George Sgouros
Journal:  Mol Cancer Ther       Date:  2013-07-19       Impact factor: 6.261

5.  Branched amphiphilic peptide capsules: cellular uptake and retention of encapsulated solutes.

Authors:  Pinakin Sukthankar; L Adriana Avila; Susan K Whitaker; Takeo Iwamoto; Alfred Morgenstern; Christos Apostolidis; Ke Liu; Robert P Hanzlik; Ekaterina Dadachova; John M Tomich
Journal:  Biochim Biophys Acta       Date:  2014-02-22

Review 6.  A review of solute encapsulating nanoparticles used as delivery systems with emphasis on branched amphipathic peptide capsules.

Authors:  Sheila M Barros; Susan K Whitaker; Pinakin Sukthankar; L Adriana Avila; Sushanth Gudlur; Matt Warner; Eduardo I C Beltrão; John M Tomich
Journal:  Arch Biochem Biophys       Date:  2016-02-27       Impact factor: 4.013

Review 7.  Actinium-225 in targeted alpha-particle therapeutic applications.

Authors:  David A Scheinberg; Michael R McDevitt
Journal:  Curr Radiopharm       Date:  2011-10

Review 8.  α-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies-Part 1.

Authors:  Sophie Poty; Lynn C Francesconi; Michael R McDevitt; Michael J Morris; Jason S Lewis
Journal:  J Nucl Med       Date:  2018-03-15       Impact factor: 10.057

Review 9.  Chemical aspects of metal ion chelation in the synthesis and application antibody-based radiotracers.

Authors:  Eszter Boros; Jason P Holland
Journal:  J Labelled Comp Radiopharm       Date:  2018-03-12       Impact factor: 1.921

Review 10.  Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations.

Authors:  Mehran Makvandi; Edouard Dupis; Jonathan W Engle; F Meiring Nortier; Michael E Fassbender; Sam Simon; Eva R Birnbaum; Robert W Atcher; Kevin D John; Olivier Rixe; Jeffrey P Norenberg
Journal:  Target Oncol       Date:  2018-04       Impact factor: 4.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.